Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01168310 · ClinicalTrials.gov registry record · Phase 2

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 study, sponsored by Dey.

Completed
Registry status
Phase 2
Development phase
468
Enrollment target

NCT01168310 is a Phase 2 study that has completed, run by Dey. The registered enrollment target is 468 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01168310, a Phase 2 study, has completed, sponsored by Dey.

COMPLETED
Registry status
Phase 2
Development phase
468 participants
Enrollment target

Study Summary

This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

Interventions

  • DRUG Fluticasone Propionate/Formoterol Fumarate

Trial Details

FieldValue
Enrollment Target 468 participants
Start Date 2010-08
Est. Completion 2011-10
Phase Phase 2

Sponsor

Dey

21 total trials

What the Registry Record Tells You About NCT01168310

The ClinicalTrials.gov registry entry for NCT01168310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fluticasone Propionate/Formoterol Fumarate is the first listed.

NCT01168310 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01168310 about?

NCT01168310 is a clinical study titled "A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

What is the current status of trial NCT01168310?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 468 participants. The study started on 2010-08. Estimated completion is 2011-10.

What interventions are being tested in trial NCT01168310?

The interventions under investigation include: Fluticasone Propionate/Formoterol Fumarate (DRUG).

Who is sponsoring clinical trial NCT01168310?

This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.